Investors' belief in the company's poor revenue performance is likely causing its low P/S ratio. The company's bleak revenue outlook is contributing to its low P/S. These conditions form a barrier for the share price at these levels.
Shanghai Henlius Biotech's statutory profit might not fully reflect the company's underlying earning capacity due to unusual item expense. The change from loss to profit is a positive turn for the firm.
復宏漢霖に関するコメント
UOBKH: Healthcare – China (Overweight)
UOBKH: Healthcare – China (Overweight) - Alpha Edge Investing
$薬明生物(02269.HK)$$無錫薬明康徳(02359.HK)$$信達生物製薬(01801.HK)$$杭州啓明(02500.HK)$$復宏漢霖(02696.HK)$$Aier Eye Hospital Group(300015.SZ)$$Shenzhen Mindray Bio-Medical Electronics(300760.SZ)$
DBS: China Healthcare Sector – Pharmaceutical Packaging
$微創医療科学(00853.HK)$$山東威高(01066.HK)$$石薬集団(01093.HK)$$国薬(01099.HK)$$鳳凰医療(01515.HK)$$康臣薬業(01681.HK)$$春立医療(01858.HK)$$環球医療(02666.HK)$$復宏漢霖(02696.HK)$$B-Soft Co.,Ltd.(300451.SZ)$$Guangxi LiuYao Group(603368.SH)$$百済神州(06160.HK)$
DBS: China Biotech Sector
$百済神州(06160.HK)$$石薬集団(01093.HK)$$復宏漢霖(02696.HK)$$微創医療科学(00853.HK)$$山東威高(01066.HK)$$国薬(01099.HK)$$鳳凰医療(01515.HK)$$康臣薬業(01681.HK)$$春立医療(01858.HK)$$環球医療(02666.HK)$$復宏漢霖(02696.HK)$$B-Soft Co.,Ltd.(300451.SZ)$$Guangxi LiuYao Group(603368.SH)$$百済神州(06160.HK)$
まだコメントはありません